Global S&T Development Trend Analysis Platform of Resources and Environment
DOI | 10.1038/s41467-018-05750-z |
Insufficient antibody validation challenges oestrogen receptor beta research | |
Andersson, Sandra1; Sundberg, Marten2; Pristovsek, Nusa1; Ibrahim, Ahmed3,4; Jonsson, Philip5,8; Katona, Borbala1; Clausson, Carl-Magnus1; Zieba, Agata1; Ramstrom, Margareta2; Soderberg, Ola6; Williams, Cecilia3,5,7; Asplund, Anna1 | |
2017-06-15 | |
发表期刊 | NATURE COMMUNICATIONS |
ISSN | 2041-1723 |
出版年 | 2017 |
卷号 | 8 |
文章类型 | Article |
语种 | 英语 |
国家 | Sweden; Egypt; USA |
英文摘要 | The discovery of oestrogen receptor beta (ER beta/ESR2) was a landmark discovery. Its reported expression and homology with breast cancer pharmacological target ER alpha (ESR1) raised hopes for improved endocrine therapies. After 20 years of intense research, this has not materialized. We here perform a rigorous validation of 13 anti-ER beta antibodies, using well-characterized controls and a panel of validation methods. We conclude that only one antibody, the rarely used monoclonal PPZ0506, specifically targets ER beta in immunohistochemistry. Applying this antibody for protein expression profiling in 44 normal and 21 malignant human tissues, we detect ER beta protein in testis, ovary, lymphoid cells, granulosa cell tumours, and a subset of malignant melanoma and thyroid cancers. We do not find evidence of expression in normal or cancerous human breast. This expression pattern aligns well with RNA-seq data, but contradicts a multitude of studies. Our study highlights how inadequately validated antibodies can lead an exciting field astray. |
领域 | 资源环境 |
收录类别 | SCI-E |
WOS记录号 | WOS:000403317200001 |
WOS关键词 | NEGATIVE BREAST-CANCER ; BI-FACETED ROLE ; ER-BETA ; DIFFERENTIAL EXPRESSION ; REPRODUCTIVE PHENOTYPES ; ALPHA ; PROSTATE ; PROGNOSIS ; CELLS ; LOCALIZATION |
WOS类目 | Multidisciplinary Sciences |
WOS研究方向 | Science & Technology - Other Topics |
URL | 查看原文 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/203972 |
专题 | 资源环境科学 |
作者单位 | 1.Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, S-75185 Uppsala, Sweden; 2.Uppsala Univ, Dept Chem, Sci Life Lab, S-75123 Uppsala, Sweden; 3.KTH Royal Inst Technol, Sch Biotechnol, Div Prote & Nanotechnol, Sci Life Lab, S-17121 Solna, Sweden; 4.Natl Res Ctr, Div Pharmaceut Ind, Dokki 12622, Egypt; 5.Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; 6.Uppsala Univ, Dept Pharmaceut Biosci, S-75124 Uppsala, Sweden; 7.Karolinska Inst, Dept Biosci & Nutr, S-14183 Stockholm, Sweden; 8.Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Human Oncol & Pathogenesis Program, New York, NY 10065 USA |
推荐引用方式 GB/T 7714 | Andersson, Sandra,Sundberg, Marten,Pristovsek, Nusa,et al. Insufficient antibody validation challenges oestrogen receptor beta research[J]. NATURE COMMUNICATIONS,2017,8. |
APA | Andersson, Sandra.,Sundberg, Marten.,Pristovsek, Nusa.,Ibrahim, Ahmed.,Jonsson, Philip.,...&Asplund, Anna.(2017).Insufficient antibody validation challenges oestrogen receptor beta research.NATURE COMMUNICATIONS,8. |
MLA | Andersson, Sandra,et al."Insufficient antibody validation challenges oestrogen receptor beta research".NATURE COMMUNICATIONS 8(2017). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论